A Phase 1 interventional study of Digoxin 250 MCG Oral Tablet and Spironolactone 25 mg/ 5 mL S/F Suspension in Drug Drug Interaction, sponsored by CMP Development, LLC. Completed at 1 site in India. Open to participants aged 20 Years to 35 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-05-01.
Sponsored by CMP Development, LLC · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
An open label, balanced, randomized, single-dose, two-treatment, two-sequence, two-period, crossover oral drug-drug interaction study of spironolactone (perpetrator) and Digoxin (substrate drug) in healthy adult human subjects under fasting condition.
Drug interaction studies between spironolactone and digoxin, particularly studies in which digoxin was administered intravenously (Waldorf, S 1978; Fenster, P.E. 1984), indicate that spironolactone may decrease the renal clearance of digoxin by 18-25%, and increase the (area under curve) AUC of digoxin by 35-44%. Although the radioimmunoassay used in the study may be confounded, these results suggest that inhibition of P-gp in the renal proximal tubules may be possible. To account for possible renal P-gp inhibition, subjects in the test group will be pretreated with spironolactone for about 5 days to allow accumulation of some of the metabolites which have a long half-life (e.g., canrenone \~33 hours) and continue to be treated with spironolactone while digoxin is renally eliminated from the body. Based on this assessment, the FDA suggested study design is Treatment A: Single dose of digoxin alone. Treatment B: Digoxin + Spironolactone; Day 1- 9: Spironolactone single dose; Day 6: Digoxin single oral dose.
Also, digoxin has a long half-life of 1.5-2 days, and the Pharmacokinetic (PK) sampling scheme of up to 72 hours may not be enough to characterize the elimination kinetics of digoxin. Hence, the plasma concentrations of digoxin up to 96 hours (4 days) postdose is considered This will allow you to detect possible differences in the clearance of digoxin mediated by an interaction with P-gp in the renal proximal tubules.
The study also involves collecting urine samples and measuring renal clearance (CLR) and unchanged drug excreted in urine (fe) for digoxin.
CMP Development, LLC is the lead sponsor of 2 studies on the registry; 1 is open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Volunteers who have used implanted or injected hormonal anytime during the 6 months prior to study or used hormonal contraceptives within 14 days before dosing.
-
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
14 Subjects first administered with LANOXIN® (digoxin) USP 250 mcg (Substrate drug) on Day 6 of in house, after overnight fasting of at least 10.00 hours. After washout period of 28 days, these 14 subjects were administered with Spironolactone Oral Suspension 100 mg (perpetrator, Carospir® Oral Suspension 20 mL of 25 mg / 5 mL) from day 1 to day 5 and on day 6 the after overnight fasting of at least 10.00 hours, subject was administered with LANOXIN® (digoxin) USP 250 mcg (substrate drug) + Spironolactone Oral Suspension 100 mg (perpetrator; Carospir® Oral Suspension 20 mL of 25 mg / 5 mL). From day 7 to day 9 the subjects were administered with Spironolactone Oral Suspension 100 mg (perpetrator; Carospir® Oral Suspension 20 mL of 25 mg / 5 mL).
Drug: Digoxin 250 MCG Oral Tablet
14 Subjects first administered with Spironolactone Oral Suspension 100 mg (perpetrator, Carospir® Oral Suspension 20 mL of 25 mg / 5 mL) from day 1 to day 5 and on day 6 the after overnight fasting of at least 10.00 hours, subject was administered with LANOXIN® (digoxin) USP 250 mcg (substrate drug) + Spironolactone Oral Suspension 100 mg (perpetrator; Carospir® Oral Suspension 20 mL of 25 mg / 5 mL). From day 7 to day 9 the subjects were administered with Spironolactone Oral Suspension 100 mg (perpetrator; Carospir® Oral Suspension 20 mL of 25 mg / 5 mL). After washout period of 28 days these 14 Subjects administered with LANOXIN® (digoxin) USP 250 mcg (Substrate drug) on Day 6 of in house, after overnight fasting of at least 10.00 hours
Drug: Spironolactone 25 mg/ 5 mL S/F Suspension
The intervention is for study of drug drug interaction of digoxin when administered with spironolactone oral suspension
Also known as: Spironolactone Oral Suspension 20 mL of 25 mg/mL
Drug page: Spironolactone
The intervention is for study of drug drug interaction of digoxin when administered with spironolactone oral suspension
Also known as: DDI Spironolactone oral suspension interaction with digoxin
Dogoxin Plasma Data for Cmax
Primary Pharmacokinetic parameter The following pharmacokinetic parameters for Digoxin were obtained using non-compartmental method Cmax, AUC0-96, and tmax using plasma data, Renal clearance (CLR) /Percent Recovered, Unchanged drug excreted in urine (fe)/Amount Recovered using urine data.
Time frame: 4 days
Digoxin Plasma Data for AUC0-96
Area under the plasma concentration versus time curve from time 0 to the 96 hour time point concentration.
Time frame: 4 days
Digoxin Plasma Data for Tmax
If the maximum value occurs at more than one time point, Tmax is defined as the first time point with this value.
Time frame: 4 days
ECG Measurement Will be Performed to Evaluate Any Changes in the QT Interval
ECG will be performed at 1.00 and 3.00 hours post dose in each period on Day 6 and at check-out of each period of the study
Time frame: 4 days
Renal Clearance (CLR)/Percent Recovered
Summary Statistics for Untransformed Urine PK Parameters of digoxin Per Treatment-Renal clearance (CLR)/Percent Recovered
Time frame: 04 Days
Unchanged Drug Excreted in Urine (fe)/ Amount Recovered
Summary of Urine Pharmacokinetic parameters for digoxin -unchanged drug excreted in urine (fe)/ Amount Recovered
Time frame: 04 Days
| Milestone | LANOXIN First, Then Carospir | First Carospir, Then LANOXIN |
|---|---|---|
| Started | 14 | 14 |
| Completed | 14 | 14 |
| Not completed | 0 | 0 |
| Milestone | LANOXIN First, Then Carospir | First Carospir, Then LANOXIN |
|---|---|---|
| Started | 14 | 14 |
| Completed | 14 | 14 |
| Not completed | 0 | 0 |
Primary Pharmacokinetic parameter The following pharmacokinetic parameters for Digoxin were obtained using non-compartmental method Cmax, AUC0-96, and tmax using plasma data, Renal clearance (CLR) /Percent Recovered, Unchanged drug excreted in urine (fe)/Amount Recovered using urine data.
| pg/mL | Drug-Drug Interaction Study |
|---|---|
| Treatment A | 1530.188 ± 502.810 |
| Treatment B | 2432.908 ± 870.562 |
Area under the plasma concentration versus time curve from time 0 to the 96 hour time point concentration.
| pg.hr/mL | Drug-Drug Interaction Study |
|---|---|
| Treatment A | 13715.974 ± 2669.003 |
| Treatment B | 16551.500 ± 4108.500 |
If the maximum value occurs at more than one time point, Tmax is defined as the first time point with this value.
| hr | Drug-Drug Interaction Study |
|---|---|
| Treatment A | 0.744 ± 0.195 |
| Treatment B | 0.901 ± 0.569 |
ECG will be performed at 1.00 and 3.00 hours post dose in each period on Day 6 and at check-out of each period of the study
Results for this outcome have not been posted.
Summary Statistics for Untransformed Urine PK Parameters of digoxin Per Treatment-Renal clearance (CLR)/Percent Recovered
| % recovered | Drug-Drug Interaction Study |
|---|---|
| Treatment A | 54.687 ± 29.158 |
| Treatment B | 53.378 ± 21.256 |
Summary of Urine Pharmacokinetic parameters for digoxin -unchanged drug excreted in urine (fe)/ Amount Recovered
| nanograms | Drug-Drug Interaction Study |
|---|---|
| Treatment A | 136717.72 ± 72895.492 |
| Treatment B | 133446.07 ± 53141.044 |
Collected over 9 days for period 18 Days for 2 periods. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Treatment-A- Single Dose of Digoxin (LANOXIN) | 0/28 (0%) | 0/28 (0%) | 0/28 (0%) |
| Treatment-B-Digoxin (LANOXIN) + Spiranolactone (Carospir) | 0/28 (0%) | 0/28 (0%) | 0/28 (0%) |
On Day 6 of each period, after overnight fasting for at least 10.00 hours the subjects were dosed either with the Treatment (A) \[LANOXIN® (digoxin) USP 250 mcg (substrate drug)\] or Treatment (B) \[LANOXIN® (digoxin) USP 250 mcg (substrate drug) + Spironolactone Oral Suspension 100 mg (Perpetrator; Carospir® Oral Suspension 20 mL of 25 mg / 5 mL)\] as per the randomization scheme.
| Age, Categorical(Participants) | Drug-Drug Interaction Study |
|---|---|
| <=18 years | 0 |
| Between 18 and 65 years | 28 |
| >=65 years | 0 |
| Age, Continuous(Years) | Drug-Drug Interaction Study |
|---|---|
| Mean | 29 (23 to 33) |
| Sex: Female, Male(Participants) | Drug-Drug Interaction Study |
|---|---|
| Female | 0 |
| Male | 28 |
| Race and Ethnicity Not Collected(Participants) | Drug-Drug Interaction Study |
|---|
| Region of Enrollment(participants) | Drug-Drug Interaction Study |
|---|---|
| India | 28 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Mar 2019 to primary completion in Apr 2019, 1 month.
Results were first posted in May 2023, 4 years after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Digoxin · Spironolactone
CMP Development, LLC